Product Re-Launch Excellence: Transforming Lackluster Pharmaceutical Products Into Market Success Stories
Product re-launch is the hobgoblin of the pharmaceutical and biotech sector. Few brand leaders ever aspire to this marketing challenge. Yet many find they and their companies must confront re-launch scenarios – or sacrifice hundreds of millions of dollars invested in underperforming products.
A hallmark of great brand and lifecycle management excellence is the ability to successfully re-launch a product that has not achieved its potential upon market entry. This business situation occurs notably at two critical moments in a product’s lifecycle:
- The first appearance is product re-launch due to a miscalculation in the product launch plan. Pfizer's Zithromax is a notable example of a product that misjudged the market, corrected pricing, packaging, sales force support and positioning – and then re-launched. Zithromax is now a multi-billion dollar annual brand – and a “hall of fame” candidate for re-launch excellence.
- Another venue for re-launch is during market entry of a product combination or major line extension. In this instance, two existing products are combined and must launch a new or complementary positioning in the market. Advair and Prevacid NapraPac are examples of smart combinations.
This Best Practices, LLC benchmarking study probed best practices and lessons learned in successful product re-launches. This study also includes two highly successful re-launch case studies: the history and lessons learned from Zithromax and Wellbutrin – two blockbuster products that nearly failed in the marketplace during their initial launches. With interviews and extensive survey data drawn from executives at leading pharmaceutical and biotech companies, this report serves as a guide to achieve an excellent product re-launch.
Sales and Marketing > New Product Development and Launch d
Industries Profiled:
Consumer Products; Diagnostic; Pharmaceutical; Biotech; Health Care
Companies Profiled:
Bayer Healthcare; Sanofi-aventis; UCB Pharma; Schering-Plough; Roche; Pfizer; Novartis; Merck; AstraZeneca; DSM Pharmaceutical; Abbott Laboratories; Eli Lilly; GlaxoSmithKline l
Study Snapshot
Product Re-Launch Excellence: Transforming Lackluster Pharmaceutical Products Into Market Success Stories (SM-170) benchmarks the perspectives of 19 brand leaders from a class of 14 leading pharmaceutical companies. This report will help executives gain the insights necessary to: set re-launch strategy, re-define brand character, invigorate sales support and set the optimal investment level. After identifying areas for improvement, your organization can close performance gaps in re-launching products and employ changes that will support and sustain change in your organization.
Back to Top
Key Findings
Following, are some of the higher-level key findings from the study. Examples of more tactical and in-depth practices are included in the complimentary summary available for download by clicking on "Download FREE Excerpt" in the column on the right. Insights include:
- Setting Re-launch Strategy: The pathway to re-launch success is paved by careful analysis of what went wrong during initial launch.
- Selecting Your Pathway To Success: Assess each re-launch as a unique market situation that requires customized strategy fitting and tactical alignment.
- Redefining Product Character & Position: Shape a new core message that serves as the catalyst for the revised product positioning.
- Winning The Hearts & Minds of The Sales Organization: Sales force strategy needs to fit the re-launch approach and scope to place resources where they will make a difference.
- Winning The Marketing Investment Resources To Succeed: Product re-launch success requires the coordination of multiple factors – first of which is determining the marketing resources required to carry out the re-launch strategy.
Back to Top
Related Research:
R&D Quality Assurance Excellence Library
 |
A must-have for all pharmaceutical, biotech and medical device manufacturing executives, this Best Practices' R&D Quality Assurance bundle tells you everything you need to know about quality... (ID OPS-95)
Companies Profiled: aaiPharma, Sanofi-aventis, Abbott, Abbott Laboratories, more ...
Price: $21100.00 Free Excerpt Available
| |
Best Practices in Global Pharmaceutical Launches
 |
Discover how the world's leading pharmaceutical companies develop global launch strategies, manage launch teams, cultivate thought leader support, integrate marketing activities, and conduct a host of other critical launch activities... (ID SM-120)
Companies Profiled: Merck, Sanofi-aventis, Eli Lilly, Wyeth, more ...
Price: $7000.00 Free Excerpt Available
| |
|